JP2009515816A - フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 - Google Patents
フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 Download PDFInfo
- Publication number
- JP2009515816A JP2009515816A JP2008525251A JP2008525251A JP2009515816A JP 2009515816 A JP2009515816 A JP 2009515816A JP 2008525251 A JP2008525251 A JP 2008525251A JP 2008525251 A JP2008525251 A JP 2008525251A JP 2009515816 A JP2009515816 A JP 2009515816A
- Authority
- JP
- Japan
- Prior art keywords
- omega
- weight
- percent
- formulation
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
プラバスタチン亜鉛塩の製造
脱イオン水に溶解されたプラバスタチンナトリウムの2当量を、脱イオン水中に塩化亜鉛の1当量を有する溶液と反応させる。結晶性プラバスタチン亜鉛の沈殿が室温で直ちに生じる。得られる塩は、2:1プラバスタチン対亜鉛の塩であった。プラバスタチン亜鉛の製造および特性決定は米国特許出願公開第20060034815号の実施例7においてより完全に記述されている。
プラバスタチン亜鉛塩の存在下でのフェノフィブレート溶解度
プラバスタチン亜鉛の2用量が使用された:10mgおよび80mg。10mgおよび80mg(活性部分のみの重量)は、亜鉛塩の重量ではそれぞれ約13gおよび106gに対応する。表2は、14および25℃における、87:13 Incromega:エタノール媒質中および70:10:10:10 Incromega:エタノール:CremophorEL:Span20媒質中(前記比率はパーセント重量で表される)のフェノフィブレートおよびプラバスタチン亜鉛の溶解度データを含む。表2における溶解度測定値は、調合液の平衡を起こさせた3〜5日後に得られた。溶解度測定値は、サンプル希釈液が70:30アセトニトリル:脱イオン水であるHPLCにより得られた。サンプルは1000のファクターで希釈された。(註:本実施例で使用されたIncromegaオイルは、CrodaによるIncromega E7010SRであった。)
Claims (16)
- フェノフィブレート、スタチンおよびω−3油を含んでなる調合物。
- 該スタチンがプラバスタチン亜鉛である、請求項1の調合物。
- 該スタチンがプラバスタチンカルシウムである、請求項1の調合物。
- 該スタチンがプラバスタチンマグネシウムである、請求項1の調合物。
- 該ω−3油がω−3エチルエステルである、請求項1の調合物。
- ω−3アルキルエステルの重量で約65.00〜約85.00%、C1−C4アルコールの重量で約5.00〜約15.00%、スタチンの重量で約10.00〜約25.00%、およびフェノフィブレートの重量で約10.00〜約20.00%を含んでなる調合物。
- 該C1−C4アルコールがエタノールである、請求項6の調合物。
- 該スタチンがプラバスタチン亜鉛である、請求項6の調合物。
- 該ω−3アルキルエステルがω−3エチルエステルである、請求項6の調合物。
- 該ω−3エチルエステルが両、EPAおよびDHAを含む、請求項9の調合物。
- EPA:DHA比が約6.8:1である、請求項10の調合物。
- EPA:DHA比が約2:1である、請求項10の調合物。
- EPA:DHA比が約1.5:1である、請求項10の調合物。
- EPA:DHA比が約1:1である、請求項10の調合物。
- 請求項6の調合物の有効量をそれを必要とする哺乳動物に投与することを含む、上昇したコレステロールレベル、アテローム性動脈硬化症、高トリグリセリド血症、冠状動脈疾患または脳血管疾患を予防、軽減または処置する方法。
- 該哺乳動物がヒトである、請求項15の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70559805P | 2005-08-04 | 2005-08-04 | |
PCT/US2006/030580 WO2007019373A2 (en) | 2005-08-04 | 2006-08-03 | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009515816A true JP2009515816A (ja) | 2009-04-16 |
Family
ID=37727947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008525251A Pending JP2009515816A (ja) | 2005-08-04 | 2006-08-03 | フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7772277B2 (ja) |
EP (1) | EP1922065A4 (ja) |
JP (1) | JP2009515816A (ja) |
KR (1) | KR20080033410A (ja) |
CN (1) | CN101500555A (ja) |
AU (1) | AU2006278444A1 (ja) |
BR (1) | BRPI0614378A2 (ja) |
CA (1) | CA2617805A1 (ja) |
IL (1) | IL189165A0 (ja) |
MX (1) | MX2008001597A (ja) |
RU (1) | RU2008108078A (ja) |
WO (1) | WO2007019373A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG155189A1 (en) * | 2004-08-06 | 2009-09-30 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
US20110196383A1 (en) * | 2009-05-05 | 2011-08-11 | Atherolysis Medical, Inc | Atherosclerotic Plaque Dissolution Composition |
PT2595597T (pt) * | 2010-07-19 | 2017-12-20 | Procaps S A | Aparelho e processo para encapsular cápsulas ou outras formas de dosagem sólida dentro de cápsulas |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
CN102357096A (zh) * | 2011-09-09 | 2012-02-22 | 北京阜康仁生物制药科技有限公司 | 一种含有他汀类药物锌盐的降血脂组合物 |
BR112014016788A8 (pt) | 2012-01-06 | 2017-07-04 | Chrysalis Pharma Ag | composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa |
EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
KR101719907B1 (ko) * | 2015-06-17 | 2017-03-24 | 동국대학교 산학협력단 | 오메가-3 인지질 기반 페노피브레이트 제제 및 이의 제조방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04257518A (ja) * | 1990-08-23 | 1992-09-11 | E R Squibb & Sons Inc | Iii型高リポ蛋白血症の予防または治療用医薬組成物 |
JP2001525363A (ja) * | 1997-12-10 | 2001-12-11 | シクロスポリン セラポイティクス リミテッド | オメガ−3脂肪酸油を含む医薬組成物 |
WO2004014872A1 (en) * | 2002-08-13 | 2004-02-19 | Astrazeneca Uk Limited | Process for preparing the calcium salt of rosuvastatin |
WO2004082667A1 (en) * | 2003-03-17 | 2004-09-30 | Pfizer Products Inc. | Treatment of type 1 diabetes with pde5 inhibitors |
JP2005522444A (ja) * | 2002-02-14 | 2005-07-28 | ランバクシー ラボラトリーズ リミテッド | アルカリ金属の添加により安定化させたアトーバスタチン製剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
AU1809499A (en) | 1997-12-10 | 1999-06-28 | Awadhesh K. Mishra | Self-emulsifying fenofibrate formulations |
US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
EP1162954A1 (en) * | 1999-03-31 | 2001-12-19 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
AU3651102A (en) * | 2000-11-29 | 2002-06-11 | Smithkline Beecham Corp | Composition containing statins and calcium for improved cardiovascular health |
EP1414496B1 (en) * | 2001-08-07 | 2010-10-20 | Galephar M/F | Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride |
NZ529913A (en) * | 2001-08-16 | 2005-03-24 | Teva Pharma | Processes for preparing calcium salt forms of statins |
EP1539117A4 (en) | 2002-06-28 | 2005-12-14 | Shire Lab Inc | FORMULATIONS BASED ON FENOFIBRATE AND / OR FENOFIBRATE DERIVATIVES HAVING IMPROVED ORAL BIOAVAILABILITY |
DE10261067A1 (de) | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
WO2005046662A2 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
KR20070038553A (ko) | 2004-08-06 | 2007-04-10 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 스타틴 약제학적 조성물 및 관련된 치료방법 |
-
2006
- 2006-08-03 RU RU2008108078/15A patent/RU2008108078A/ru not_active Application Discontinuation
- 2006-08-03 US US11/462,142 patent/US7772277B2/en not_active Expired - Fee Related
- 2006-08-03 CN CNA2006800280491A patent/CN101500555A/zh active Pending
- 2006-08-03 JP JP2008525251A patent/JP2009515816A/ja active Pending
- 2006-08-03 MX MX2008001597A patent/MX2008001597A/es unknown
- 2006-08-03 WO PCT/US2006/030580 patent/WO2007019373A2/en active Application Filing
- 2006-08-03 EP EP06800817A patent/EP1922065A4/en not_active Withdrawn
- 2006-08-03 BR BRPI0614378-4A patent/BRPI0614378A2/pt not_active IP Right Cessation
- 2006-08-03 CA CA002617805A patent/CA2617805A1/en not_active Abandoned
- 2006-08-03 KR KR1020087003700A patent/KR20080033410A/ko not_active Application Discontinuation
- 2006-08-03 AU AU2006278444A patent/AU2006278444A1/en not_active Abandoned
-
2008
- 2008-01-31 IL IL189165A patent/IL189165A0/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04257518A (ja) * | 1990-08-23 | 1992-09-11 | E R Squibb & Sons Inc | Iii型高リポ蛋白血症の予防または治療用医薬組成物 |
JP2001525363A (ja) * | 1997-12-10 | 2001-12-11 | シクロスポリン セラポイティクス リミテッド | オメガ−3脂肪酸油を含む医薬組成物 |
JP2005522444A (ja) * | 2002-02-14 | 2005-07-28 | ランバクシー ラボラトリーズ リミテッド | アルカリ金属の添加により安定化させたアトーバスタチン製剤 |
WO2004014872A1 (en) * | 2002-08-13 | 2004-02-19 | Astrazeneca Uk Limited | Process for preparing the calcium salt of rosuvastatin |
JP2006500347A (ja) * | 2002-08-13 | 2006-01-05 | アストラゼネカ・ユーケイ・リミテッド | ロスバスタチンのカルシウム塩の製造法 |
WO2004082667A1 (en) * | 2003-03-17 | 2004-09-30 | Pfizer Products Inc. | Treatment of type 1 diabetes with pde5 inhibitors |
JP2006520777A (ja) * | 2003-03-17 | 2006-09-14 | ファイザー・プロダクツ・インク | Pde5阻害剤を用いる1型糖尿病の治療 |
Non-Patent Citations (4)
Title |
---|
JPN6011025876; GREKAS, D et al: 'Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia' NEPHRON vol.88, no.4, 2001, p.329-333 * |
JPN6012020032; ELLEN,R.L. et al: 'Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemi' Am J Cardiol Vol.81, No.4A, 1998, p.60B-65B * |
JPN6012020034; CONTACOS,C. et al: 'Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with com' Arterioscler Thromb Vol.13, No.12, 1993, p.1755-62 * |
JPN6012020036; YANO,T. et al: 'Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on' Life Sci Vol.61, No.20, 1997, p.2007-15 * |
Also Published As
Publication number | Publication date |
---|---|
CN101500555A (zh) | 2009-08-05 |
AU2006278444A1 (en) | 2007-02-15 |
WO2007019373A2 (en) | 2007-02-15 |
MX2008001597A (es) | 2008-04-04 |
US20070032546A1 (en) | 2007-02-08 |
RU2008108078A (ru) | 2009-09-10 |
KR20080033410A (ko) | 2008-04-16 |
IL189165A0 (en) | 2008-11-03 |
BRPI0614378A2 (pt) | 2011-03-22 |
EP1922065A2 (en) | 2008-05-21 |
US7772277B2 (en) | 2010-08-10 |
EP1922065A4 (en) | 2009-11-11 |
CA2617805A1 (en) | 2007-02-15 |
WO2007019373A3 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009515816A (ja) | フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 | |
TWI571271B (zh) | 包含ω-3脂肪酸酯及HMG-CoA還原酶抑制劑之口服複合組成物 | |
KR101356335B1 (ko) | 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제 | |
US20140004186A1 (en) | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin | |
EP2083622A1 (en) | Omega-3 fatty acids for reduction of lp-pla2 levels | |
EP2846779A1 (en) | Compositions of statins and omega-3 fatty acids | |
US20140080889A1 (en) | Statin and Omega-3 Fatty Acids for Lipid Therapy | |
JP6073352B2 (ja) | 安定性が向上したω−3脂肪酸およびHMG−COA還元酵素阻害剤を含む経口複合製剤 | |
JP2009544701A (ja) | オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 | |
KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
KR101954568B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
KR101519887B1 (ko) | 고지혈증치료제 및 오메가-3 지방산을 함유하는 복합제제 | |
RU2398577C2 (ru) | Новые композиции фенофибрата и соответствующие способы лечения | |
KR20130003501A (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090708 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120724 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120731 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130115 |